| Literature DB >> 24553612 |
Icaro Boszczowski1, Gladys Villas Boas do Prado1, Mirian F Dalben1, Roberto C P Telles2, Maristela Pinheiro Freire1, Thaís Guimarães1, Maura S Oliveira1, Juliana F Rosa2, Robson E Soares2, Pedro Enrique Dorlhiac Llacer3, Frederico Luiz Dulley4, Silvia F Costa2, Anna S Levin1.
Abstract
AIM: The objective was to describe an outbreak of bloodstream infections by Burkholderia cepacia complex (Bcc) in bone marrow transplant and hematology outpatients.Entities:
Mesh:
Year: 2014 PMID: 24553612 PMCID: PMC4085834 DOI: 10.1590/S0036-46652014000100011
Source DB: PubMed Journal: Rev Inst Med Trop Sao Paulo ISSN: 0036-4665 Impact factor: 1.846
Fig. 1Distribution of cases over time and molecular types during an outbreak of bloodstream infections caused by Burkholderia cepacia in two outpatient units (Hematology and Bone Marrow Transplant). Hospital das Clínicas, University of São Paulo, Brazil. 2007 to March, 2008. (Only the first isolate from each patient is depicted).
Characteristics of 24 patients involved in an outbreak of bloodstream infections caused by Burkholderia cepacia in two outpatient units (Hematology and Bone Marrow Transplant). Hospital das Clínicas, University of São Paulo, Brazil. January-February, 2008
| Characteristics | |
| Male sex | 10 (42%) |
| Age (years) | |
| Mean (SD) | 34 (16.4) |
| Median (range) | 30 (2-64) |
| Outpatient unit | |
| Hematology | 13 (54%) |
| Bone marrow transplant | 11 (46%) |
| Underlying disease | |
| Hodgkin's lymphoma | 8 (33%) |
| Non-Hodgkin's lymphoma | 7 (29%) |
| Aplastic anemia | 3 (13%) |
| Chronic myelocytic leukemia | 2 (8%) |
| Myelofibrosis | 1 |
| Acute myelocytic leukemia | 1 |
| Acute lymphocytic leukemia | 1 |
| Primitive neuroectodermal tumor | 1 |
| Type of CVC | |
| Totally implanted | 13 (54%) |
| Partially implanted | 11 (46%) |
| Type of dressing used on CVC site | |
| Transparent film | 17 (71%) |
| Gauze | 7 (29%) |
| Use of chlorhexidine at CVC site | 24 (100%) |
| Under chemotherapy | 8 (33%) |
| Products administered through CVC | |
| Heparin | 24 (100%) |
| Dexamethasone | 7 (29%) |
| Teicoplanin | 7 (29%) |
| Ondansetron | 6 (25%) |
| Cefepime | 5 (21%) |
| Dipirone | 5 (21%) |
| Meropenem | 5 (21%) |
| Filgrastim | 4 (17%) |
| Ceftriaxone | 3 (13%) |
| Platelet concentrate | 3 (13%) |
| Fluconazole | 3 (13%) |
| Levofloxacin | 3 (13%) |
| Acyclovir | 2 |
| Red blood cell concentrate | 2 |
| Dimenidrate | 2 |
| CVC was used on February 11 and/or 12, 2008 | 10 (42%) |
| Days between CVC insertion and
positive blood culture | |
| Mean (SD) | 276.5 (257) |
| Median (range) | 189 (16-853) |
| Days between last use of CVC and
positive blood culture | |
| Mean (SD) | 6.4 (6.6) |
| Median (range) | 6 (1-32) |
SD: standard deviation; CVC: central venous catheter;
data available for 20 patients;
data available for 21 patients.
Fig. 2Number of case patients cared for by each healthcare worker during an outbreak of bloodstream infections caused by Burkholderia cepacia in two outpatient units. (Hematology Unit: black bars; Bone Marrow Transplant Unit: grey bars). Hospital das Clínicas, University of São Paulo, Brazil. January-February, 2008.